News & Updates

Sustained benefit with anti-TNFα less likely to lead to subsequent loss of response in IBD
Sustained benefit with anti-TNFα less likely to lead to subsequent loss of response in IBD
01 Nov 2021

Inflammatory bowel disease (IBD) patients receiving treatment with antitumour necrosis factor alpha (anti-TNFα) for more than 2 years represent a distinct group who obtain prolonged clinical benefit and tolerate maintenance treatment, according to a study.

Sustained benefit with anti-TNFα less likely to lead to subsequent loss of response in IBD
01 Nov 2021
Poor metabolic health may lead to subsequent gastrointestinal cancers
Poor metabolic health may lead to subsequent gastrointestinal cancers
31 Oct 2021
Local failure common in metastases from right-sided primary CRC treated with SABR
Local failure common in metastases from right-sided primary CRC treated with SABR
31 Oct 2021

Local failure (LF) is more likely to occur in colorectal cancer (CRC) metastases treated with stereotactic ablative radiotherapy (SABR) if originating from right-sided primary CRC compared with left-sided, a study has found. In addition, LF rates are highest with liver metastases than other metastatic sites.

Local failure common in metastases from right-sided primary CRC treated with SABR
31 Oct 2021
Patients presenting with advanced-stage pancreatic cancer reveal cracks in imaging-based surveillance
Patients presenting with advanced-stage pancreatic cancer reveal cracks in imaging-based surveillance
31 Oct 2021

High-risk individuals who develop neoplastic progression to pancreatic cancer or high-grade dysplasia can present at an advanced stage despite showing no lesions during prior imaging surveillance evaluations, a new study has found.

Patients presenting with advanced-stage pancreatic cancer reveal cracks in imaging-based surveillance
31 Oct 2021